In multivariate analysis, independent associations were found between plasma Sr 2+ concentration and both eGFR (β = −0.401, P < 0.001) and plasma fibroblast growth factor 23 (FGF23) concentration (β = 0.087, P = 0.04).
| INTRODUCTION
The element strontium (Sr 2+ ) is ranked together with calcium, magnesium and barium in the same column of the periodic table of the elements and shares major similarities with calcium. First, both elements become available in the body after absorption in the small intestine and are transported by similar proteins to be stored in bone tissue. [1] [2] [3] Second, calcium and Sr 2+ both exit the body through renal excretion as the main route via a similar transport pathway. [1] [2] [3] [4] Finally, Sr 2+ has a role analogous to calcium-albeit weaker-in several physiological processes, including blood clotting, muscle contraction and bone formation. [1] [2] [3] Food is the main source of Sr
2+
, especially leafy vegetables, fruit, seafood, spices and cereals. 5 Daily intake of Sr 2+ averages 2 mg, that is considerably lower than 1000-1500 mg calcium intake. An average person contains 47 μg Sr 2+ and 15 g calcium per kilogram body weight. 1, 4, 6 Although literature is scarce, the normal range of plasma Sr 2+ concentration has been claimed to be 228-354 nmol/L. 5 Little is known on alterations in circulating plasma Sr 2+ concentration in patients with renal function impairment. 7 Chronic kidney disease (CKD) is accompanied by pronounced changes in calcium and phosphate metabolism. 8, 9 Some key features are a tendency towards phosphate retention, 10 resulting in an increased secretion of the phosphaturic peptide hormone fibroblast growth factor 23 (FGF23) 11, 12 and an increase in plasma parathyroid hormone (PTH) concentrations. 13, 14 The latter results in increased bone turnover and therefore stimulates the release of phosphate and calcium from the bones into the circulation. 6, 11 As the plasma calcium concentration is under tight regulation, this increased bone turnover does not result in hypercalcemia. 15 It is unknown whether the changes in calcium and phosphate metabolism associated with progressive CKD also affect plasma Sr 2+ concentrations. Previously, in animal models with chronic renal failure, signs of increased Sr 2+ concentrations in serum, bone, the liver and the kidneys have been reported. [16] [17] [18] We hypothesize that alterations in mineral metabolism in CKD are associated with increased plasma Sr 2+ concentrations. Whether this subsequently results in increased renal excretion to prevent increased plasma Sr 2+ concentrations has not been studied so far. Therefore, here we investigate the association between plasma Sr 2+ concentration in diabetic kidney disease and parameters associated with an altered calcium and phosphate metabolism.
| MATERIALS AND METHODS

| Patient inclusion
The study was performed in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1), which was described previously. 19 In short, patients with type 2 diabetes mellitus (T2DM) aged 18 + years were included, and exclusion criteria were renal replacement therapy or inability to understand the informed consent. 
| Data collection
Information on medical condition, medication use and smoking habits were obtained from the electronic patient records and anamnesis. Information concerning alcohol consumption was collected through the questionnaire Food Frequency Questionnaire (FFQ). 20 Body dimensions were measured according to standard procedures. Blood pressure was measured in a supine position by an automated device (Dinamap®; GE Medical Systems, Milwaukee, WI, USA) for 15 minutes with 1-minute intervals. The mean systolic and diastolic pressure of the last three measurements was used for further analysis. Blood samples were taken by venipuncture. In addition, every patient collected 24-hour urine. Samples of blood and 24-hours urine were stored for later analysis. Unless noted otherwise, all analyses were performed using routine laboratory procedures. Notably, PTH was analysed using a second-generation immunoassay (Roche Diagnostics, Indianapolis, Indiana, USA) and FGF23 by C-terminal assay (Immutopics, California, USA). According to standard practice, plasma calcium concentration was corrected for plasma albumin concentration with the formula: corrected plasma calcium concentration (mmol/L) = plasma calcium concentration (mmol/L) + ((40 -plasma albumin concentration (g/L))*0.02).
The renal function was estimated by the CKD Epidemiology Collaboration (CKD-EPI) creatinine-based formula for estimation of the glomerular filtration rate (eGFR). 
| Statistical analyses
All statistical analyses were performed using SPSS statistics 24 .0. Variables were tested for normality using histograms. Normally distributed variables are presented as the mean and the standard deviation (SD Differences between the groups were tested using the one-way ANOVA (normal distribution), Kruskal-Wallis (skewed distribution) and chisquare tests. A two-sided P value <0.05 was considered statistically significant.
To determine the association between components of the calcium and phosphate metabolism and plasma Sr 2+ concentration, we performed multivariate linear regression analysis. Plasma Sr 2+ concentration was transformed according to its natural logarithm (LN) to achieve a normal distribution. We performed partial regression analyses to account for collinearity. All possible confounders with a P value <0.1 in univariate analysis were included in the multivariate linear regression analysis. A backward stepwise elimination with a threshold on P = 0.05 was used to select variables in the final model.
| RESULTS
| Study population
A total number of 450 patients, 58% of which were male were included and the mean age was 63 ± 9 years (Table 1) , and 58% was male. Mean BMI was 33 ± 6 kg/ m 2 and in the study population 61% of the patients had a BMI above 30 kg/m 2 . Median duration of diabetes was 11 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] years, and the glucose values of the patients were tolerably regulated with a mean HbA 1c of 57 ± 12 mmol/ mol. The majority used insulin (64%).
Of the study population, 77% had CKD stages 1-2, 20% had CKD stage 3 and 3% had CKD stages 4-5. Mean age of patients with CKD stages 1-2 was significantly lower (61 ± 9 years) than those with the other CKD stages (68 ± 7 years, P < 0.001 and 69 ± 10 years, P = 0.007). More patients had albuminuria in CKD stage 3 (47%) and CKD stages 4-5 (64%) than in CKD stages 1-2 (25%), P < 0.001. The prevalence of macrovascular disease was higher in CKD stages 4-5 (64%) than in CKD stage 3 (52%) and CKD stages 1-2 (30%), P < 0.001.
As expected, the key components of calcium and phosphate metabolism differed between CKD stages: plasma PTH concentration and plasma FGF23 concentration were significantly higher in each subsequent CKD group (P < 0.001). Plasma phosphate concentration was highest in CKD stages 4-5, although was not significantly different from the other CKD groups (P = 0.08).
Median concentration (β = −0.436, P < 0.001; Figure 1 ).
| Relationship between plasma Sr
2+ concentration and mineral metabolism components
To determine the association between plasma Sr 2+ concentration and components of calcium and phosphate metabolism, we performed linear regression analysis ( Table 2) . Because of high collinearity between individual components of the calcium and phosphate axis we performed a partial regression analysis (Table S1 ). All variables with a P < 0.10 in univariate analysis were candidates for the multivariate model. Multivariate linear regression analysis (Table 3) accumulation in CKD is supported by our finding that urinary excretion of Sr 2+ is decreased in progressive CKD.
We hypothesized that the negative correlation between plasma Sr 2+ concentration and eGFR is associated with the alterations in calcium and phosphate metabolism and bone remodelling found in CKD. Therefore, we explored associations between the plasma Sr 2+ concentration and several variables related to calcium and phosphate metabolism. We found that plasma FGF23 concentration, which is a marker of altered calcium and phosphate metabolism in CKD, 12 was correlated with plasma Sr 2+ concentration. The associations of both eGFR and FGF23 with plasma Sr 2+ concentration were independent of other components of calcium and phosphate metabolism. Because plasma calcium concentration is tightly regulated and excess calcium will be periodically excreted in the urine and faeces, 15 increased bone turnover will not result in hypercalcemia. Sr2 + and calcium both are transported by similar proteins and are stored in bone tissue. [1] [2] [3] Given this similarity of calcium and Sr
2+
, it is likely that increased bone turnover in CKD increases release of both calcium and Sr 2+ into the circulation. However, we speculate that, unlike plasma calcium concentrations, plasma Sr 2+ concentration is not tightly regulated and therefore may increase in circumstances of increased bone turnover.
2,3
The independent association between plasma FGF23 concentration and plasma Sr 2+ concentration is intriguing. However, the possibility exists that Sr 2+ plays a role in the pathophysiology of calcification in blood vessels similar to calcium: Sr 2+ has already been located in aortic valve plaques. 27 Furthermore, the drug Sr 2+ ranelate has been proven to be effective in patients with untreatable osteoporosis. 26, 28 This demonstrates that Sr 2+ certainly has some effect on the bone metabolism. Lastly, plasma Sr 2+ concentration could be a potential marker for bone remodelling.
In conclusion, our study revealed an independent inverse association between eGFR and plasma Sr 2+ concentration. Furthermore, we found an independent association between plasma Sr 2+ concentration and plasma FGF23
concentration, a marker of deranged calcium and phosphate metabolism in CKD. In the total study population, plasma Sr 2+ concentration was within the normal range.
Further research is needed to determine the mechanism of increased Sr 2+ when eGFR is low and to investigate the impact of increased Sr 2+ in bone mineralization and calcification. 
